Table 4 Reports of proton beam therapy for intrahepatic cholangiocarcinoma
From: Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers
Authors | Study design | Cases | Tumor size (cm) Median (range) | Treatment dose/fraction | Follow-up period (median) | Fiducial marker | Breathing method | OS 2Y | PFS 2Y | LC 2Y | Adverse effects grade3 (number of patient) | Adverse effects grade4 (number of patient) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
This study | Retro | 24 | 4.1 (1.0–13.4) | 48-76 Gy(RBE)/10-37Fr | 18.5 months | None | Respiratory gating system | 62% | 33% | 66% | None | 4%(1):pleural effusion(1) |
Shimizu et al 2019 Radiat Oncol [16] | Retro | 37 | 5.7 (1.5–14.0) | 66-74 Gy(RBE)/10-37Fr | 37.5 months | (+) | Respiratory gating system | 41% | 38% | 72% | 8%(3):cholangitis(3) | None |
Theodores S. Hong et al 2016 Pract Radiat Oncol [17] | Pros | 39 | 6.0 (2.2–10.9) | 58.05–67.5 Gy(RBE)/15Fr | 19.5 months | Not reffered | NR | 47% | 26% | 94% | 8%(3):liver failure and ascites(1), stomach ulcer(1), elebated bilirubin(1) | None |
Kim et al 2022 Cancers [36] | Retro | 47 | 5.2 (1.0–11.0) | 45-80 Gy(RBE)/10Fr | 18.3 month | None | Respiratory gating system | 43% | 17% | 87% | 8.5%(4):WBC decrease(2), Bilirubin increase(2) | None |
Mizumoto et al 2023 Liver Cancer [37] | Pros | 59 | 5.0 (2.0–15.2) | 60-76 Gy(RBE)/20-38Fr | 36.7 month | Not reffered | Respiratory-gated system or a motion tracking system | 46% | 24% | 77% | 6.8%(4):Bile duct stenosis(2), Dermatitis(1), Gastric hemorrhage(1) | None |